Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.

Eli Lilly (LLY) on Monday announced an agreement to acquire Kelonia Therapeutics, a privately held cancer drug developer, in a deal worth up to $7B in cash, confirming a prior report from The Wall ...

Eli Lilly researchers at work. Lilly has agreed to acquire Kelonia Therapeutics for up to $7 billion, the companies said today, in a deal that would bolster the buyer’s oncology pipeline with an early ...

April 19 (Reuters) - U.S. drugmaker Eli Lilly is in advanced talks to acquire biotech firm Kelonia Therapeutics for more than $2 billion, the Wall Street Journal reported on Sunday. A deal could be ...

Kelonia specializes in 'in vivo' CAR-T therapies for cancer Deal includes $3.25 bln upfront and milestone payments Deal price reflects strong data and sector competition - analyst April 20 (Reuters) - ...

Pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene therapy maker Kelonia Therapeutics for at least $3.25 billion, the companies announced Monday. The acquisition will grant ...

April 20 (Reuters) - U.S. drugmaker Eli Lilly ⁠will ⁠buy privately held biotech firm ⁠Kelonia Therapeutics for up to $7 billion, gaining access to experimental cancer treatments as it bolsters its ...

April 19 (Reuters) - U.S. drugmaker Eli Lilly (LLY) is in advanced talks to acquire biotech firm Kelonia ‌Therapeutics for more than $2 billion, the Wall ‌Street Journal reported on Sunday. A deal ...

U.S. drugmaker Eli Lilly is in advanced talks to acquire biotech firm Kelonia Therapeutics for more than $2 billion, The Wall Street Journal reported on Sunday. A deal could be reached as soon as ...